Table 4.
Choroidal neovascularization in the fellow eye developing from 0 to 24 months after baseline versus Barbazetto et al. [41]
| Conversions in current study (conversions/fellow eyes with dry AMD) | Conversions-Barbazetto et al. [41] (conversions/fellow eyes with dry AMD) | p-value | |
|---|---|---|---|
| TT, 12 months | 12/160 (20 %) | 100/445 (22.5 %) | 0.0001 |
| TTZ, 12 months | 3/80 (3.75 %) | 100/445 (22.5 %) | 0.00003 |
| TT, 24 months | 20/160 (12.5 %) | 151/445 (33.9 %) | 0.0000006 |
| TTZ, 24 months | 5/80 (6.25 %) | 151/445 (33.9 %) | 1 × 1.0−14 |
TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, CFT central foveolar thickness